|
Mar 3
|
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
|
|
Feb 28
|
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
|
|
Feb 15
|
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming
|
|
Jan 3
|
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
|
|
Sep 26
|
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
|
|
Aug 9
|
New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET
|
|
Aug 9
|
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
|
|
May 15
|
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
|
|
May 15
|
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
|
|
May 2
|
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
|
|
Apr 25
|
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
|
|
Apr 23
|
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
|
|
Mar 21
|
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
|
|
Mar 19
|
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Q4 2023 Acurx Pharmaceuticals Inc Earnings Call
|
|
Mar 18
|
We Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth Carefully
|
|
Mar 18
|
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
|
Mar 4
|
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
|
|
Feb 27
|
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
|
|
Feb 23
|
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
|